Recursion Pharmaceuticals (RXRX) Cash from Financing Activities (2020 - 2026)

Recursion Pharmaceuticals' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$3.5 million for Q1 2026.

• Quarterly Cash from Financing Activities fell 108.56% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $477.5 million (up 44.38% YoY) and the FY2025 annual result came in at $521.5 million, up 71.49% from the prior year.
• Cash from Financing Activities was -$3.5 million for Q1 2026 at Recursion Pharmaceuticals, down from $132.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $263.1 million in Q2 2024 and bottomed at -$3.5 million in Q1 2026.
• A 5-year average of $65.7 million and a median of $16.5 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 6848.03% — and 2026, when it slumped 108.56%.
• Recursion Pharmaceuticals' Cash from Financing Activities stood at $147.3 million in 2022, then plunged by 45.23% to $80.7 million in 2023, then tumbled by 86.81% to $10.6 million in 2024, then surged by 1140.77% to $132.0 million in 2025, then plunged by 102.63% to -$3.5 million in 2026.
• Business Quant data shows RXRX's Cash from Financing Activities at -$3.5 million in Q1 2026, $132.0 million in Q4 2025, and $251.3 million in Q3 2025.